Table 1.
Non-recurrence (N = 281) | Recurrence (N = 50) | p value | |
---|---|---|---|
Gender (n) | 0.095 | ||
Male | 225 | 45 | |
Female | 56 | 5 | |
Age (years) | 55.38 ± 0.475 | 52.14 ± 1.146 | 0.006* |
HBsAg (n) | 0.01* | ||
Negative | 61 | 3 | |
Positive | 220 | 47 | |
AFP (ng/ml) | 477.88 ± 164.67 | 4882.72 ± 2509.78 | 0.000* |
No. of tumors (n)a | 1.94 ± 0.10 | 3.34 ± 0.43 | 0.002* |
The largest size of tumor (cm)a | 3.02 ± 0.08 | 4.15 ± 0.43 | 0.003* |
Macrovascular invasion (n)a | 0.000* | ||
No | 264 | 39 | |
Yes | 7 | 9 | |
TNM staging (n)a | 0.000* | ||
I | 109 | 9 | |
II | 144 | 25 | |
III | 14 | 13 | |
Milan criteria (n)a | 0.000* | ||
Within criteria | 192 | 20 | |
Beyond criteria | 81 | 29 | |
UCSF criteria (n)a | 0.000* | ||
Within criteria | 222 | 21 | |
Beyond criteria | 51 | 28 | |
Vascular permeation (n)a | 0.000* | ||
No | 190 | 18 | |
Yes | 71 | 29 | |
Tumor differentiation (n)a | 0.025* | ||
Well-differentiated | 78 | 5 | |
Moderately differentiated | 156 | 33 | |
Poorly differentiated | 12 | 5 | |
Undifferentiated | 2 | 0 | |
Graft weight to recipient ESLV (%) (n)a | 0.018* | ||
<60% | 145 | 35 | |
≥60% | 134 | 15 |
ESLV estimated standard liver volume.
*p < 0.05.
aTotal number less than 331 due to missing data.